PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer

Cancer Medicine

Volumn 4, Issue 3, 2015, Pages 371-382

  Manceau, Gilles ^a,b,c   Marisa, Laetitia ^d   Boige, Valérie ^a,e   Duval, Alex ^c,f   Gaub, Marie Pierre ^g,h   Milano, Gérard ⁱ   Selves, Janick ^j   Olschwang, Sylviane ^k,l,m   Jooste, Valérie ⁿ   le Legrain, Michè ^g   Lecorre, Delphine ^a   Guenot, Dominique ^h   Etienne Grimaldi, Marie Christine ⁱ   Kirzin, Sylvain ^j   Martin, Laurent ⁿ   Lepage, Come ⁿ   Bouvier, Anne Marie ⁿ   Laurent Puig, Pierre ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSTITUT UNIVERSITAIRE DE FRANCE   (France)

^d Ligue Nationale Contre le Cancer ^*  (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g HÔPITAL DE HAUTEPIERRE   (France)

^h UNIVERSITÉ DE STRASBOURG   (France)

ⁱ CENTRE ANTOINE LACASSAGNE   (France)

^j CANCER RESEARCH CENTER OF TOULOUSE   (France)

^k TIMONE HOSPITAL   (France)

^l Hôpital Privé Clairval   (France)

^m Hospital Ambroise Pare   (France)

ⁿ DIJON UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Biomarker; Colon cancer; Microsatellite instability; Mismatch repair; Mutations; PIK3CA; Prognosis

Indexed keywords

B RAF KINASE; GENOMIC DNA; K RAS PROTEIN; PIK3CA PROTEIN; PROTEIN; UNCLASSIFIED DRUG; MICROSATELLITE DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; COLON CANCER; COLON RESECTION; COMPARATIVE STUDY; EXON; FEMALE; GENE SEQUENCE; GENETIC ANALYZER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE STABLE COLON CANCER; MISMATCH REPAIR; MULTICENTER STUDY; POINT MUTATION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SOMATIC MUTATION; VERY ELDERLY; WILD TYPE; CLINICAL TRIAL; COLONIC NEOPLASMS; FRANCE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; FEMALE; FRANCE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84979852530     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.370     Document Type: Article

References (50)

1. Vivanco, I., and C. L. Sawyers . 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2:489-501.
2. Forbes, SA., N. Bindal, S. Bamford, C. Cole, C. Y. Kok, D. Beare, et al. 2011. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 39:D945-D950.
3. Manning, B. D., and L. C. Cantley . 2007. AKT/PKB signaling: navigating downstream. Cell 129:1261-1274.
4. Samuels, Y., Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, et al. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554.
5. Samuels, Y., L.A., Diaz Jr., O. Schmidt-Kittler, J. M. Cummins, L. Delong, I. Cheong, et al. 2005. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7:561-573.
6. Ikenoue, T., F. Kanai, Y. Hikiba, T. Obata, Y. Tanaka, J. Imamura, et al. 2005. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65:4562-4567.
7. Guo, X. N., A. Rajput, R. Rose, J. Hauser, A. Beko, K. Kuropatwinski, et al. 2007. Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. Cancer Res. 67:5851-5858.
8. Engelman, J. A. 2009. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9:550-562.
9. Ihle, N., T. R. Williams, S. Chow, W. Chew, M. I. Berggren, G. Paine-Murrieta, et al. 2004. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 3:763-772.
10. Howes, A. L., G. G. Chiang, E. S. Lang, C. B. Ho, G. Powis, K. Vuori, and R. T. Abraham . 2007. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol. Cancer Ther. 6:2505-2514.
11. Ihle, N. T., and G. Powis . 2010. Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol. Aspects Med. 31:135-144.
12. Ihle, N., T. R. Lemos Jr, P. Wipf, A. Yacoub, C. Mitchell, D. Siwak, et al. 2009. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 69:143-150.
13. Tanaka, H., M. Yoshida, H. Tanimura, T. Fujii, K. Sakata, Y. Tachibana, et al. 2011. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin. Cancer Res. 17:3272-3281.
14. Zhang, H., G. Liu, M. Dziubinski, Z. Yang, S. P. Ethier, and G. Wu . 2008. Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res. Treat. 112:217-227.
15. Serra, V., B. Markman, M. Scaltriti, P. J. Eichhorn, V. Valero, M. Guzman, et al. 2008. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68:8022-8030.
16. Abubaker, J., P. Bavi, S. Al-Harbi, M. Ibrahim, A. K. Siraj, N. Al-Sanea, et al. 2008. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 27:3539-3545.
17. Ogino, S., K. Nosho, G. J. Kirkner, K. Shima, N. Irahara, S. Kure, et al. 2009. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J. Clin. Oncol. 27:1477-1484.
18. Kato, S., S. Iida, T. Higuchi, T. Ishikawa, Y. Takagi, M. Yasuno, et al. 2007. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int. J. Cancer 121:1771-1778.
19. Liao, X., T. Morikawa, P. Lochhead, Y. Imamura, A. Kuchiba, M. Yamauchi, et al. 2012. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin. Cancer Res. 18:2257-2268.
20. Farina Sarasqueta, A. E., C. Zeestraten, T. vanWezel, G. Van Lijnschoten, R. Van Eijk, J. W. Dekker, et al. 2011. PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell. Oncol. (Dordr.) 34:523-531.
21. Day, F. L., R. N. Jorissen, L. Lipton, D. Mouradov, A. Sakthianandeswaren, M. Christie, et al. 2013. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin. Cancer Res. 19:3285-3296.
22. Ogino, S., X. Liao, Y. Imamura, M. Yamauchi, N. J. McCleary, K. Ng, et al. 2013. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J. Natl. Cancer Inst. 105:1789-1798.
23. Popat, S., R. Hubner, and R. S. Houlston . 2005. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23:609-618.
24. Barault, L., N. Veyrie, V. Jooste, D. Lecorre, C. Chapusot, J. M. Ferraz, et al. 2008. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int. J. Cancer 122:2255-2259.
25. Chauvenet, M., V. Cottet, C. Lepage, V. Jooste, J. Faivre, and A. M. Bouvier . 2011. Trends in colorectal cancer incidence: a period and birth-cohort analysis in a well-defined French population. BMC Cancer 11:282.
26. Edge, S. B., D. R. Byrd, C. C. Compton, A. G. Fritz, F. L. Green, and A. Trotti . 2009. Colon and rectum. Pp. 143-164 in S. Edge, D. Byrd, and C. Compton, et al., eds. AJCC cancer staging manual. 7th ed. Springer, New York, NY.
27. Lievre, A., J. B. Bachet, V. Boige, A. Cayre, D. Le Corre, E. Buc, et al. 2008. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26:374-379.
28. Boland, C. R., S. N. Thibodeau, S. R. Hamilton, D. Sidransky, J. R. Eshleman, R. W. Burt, et al. 1998. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58:5248-5257.
29. Chapusot, C., L. Martin, P. Laurent-Puig, T. Ponnelle, N. Cheynel, A. M. Bouvier, et al. 2004. What is the best way to assess microsatellite instability status in colorectal cancer? Study on a population base of 462 colorectal cancers. Am. J. Surg. Pathol. 28:1553-1559.
30. Weisenberger, D., J. K. D. Siegmund, M. Campan, J. Young, T. I. Long, M. A. Faasse, et al. 2006. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38:787-793.
31. West, N. P., E. J. Morris, O. Rotimi, A. Cairns, P. J. Finan, and P. Quirke . 2008. Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. Lancet Oncol. 9:857-865.
32. Andre, T., C. Boni, M. Navarro, J. Tabernero, T. Hickish, C. Topham, et al. 2009. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27:3109-3116.
33. Gunderson, L., L. J. M. Jessup, D. J. Sargent, F. L. Greene, and A. K. Stewart . 2010. Revised TN categorization for colon cancer based on national survival outcomes data. J. Clin. Oncol. 28:264-271.
34. Andreyev, H., J. A. R. Norman, D. Cunningham, J. Oates, B. R. Dix, B. J. Iacopetta, et al. 2001. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br. J. Cancer 85:692-696.
35. Ogino, S. J., A. Meyerhardt, N. Irahara, D. Niedzwiecki, D. Hollis, L. B. Saltz, et al. 2009. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin. Cancer Res. 15:7322-7329.
36. Russo, A., V. Bazan, B. Iacopetta, D. Kerr, T. Soussi, and N. Gebbia . 2005. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol. 23:7518-7528.
37. Ogino, S., K. Shima, J. A. Meyerhardt, N. J. McCleary, K. Ng, D. Hollis, et al. 2012. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin. Cancer Res. 18:890-900.
38. Schmoll, H., J. E. Van Cutsem, A. Stein, V. Valentini, B. Glimelius, K. Haustermans, et al. 2012. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann. Oncol. 23:2479-2516.
39. Quirke, P., R. Steele, J. Monson, R. Grieve, S. Khanna, J. Couture, et al. 2009. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373:821-828.
40. Gerard, J., P. T. Conroy, F. Bonnetain, O. Bouche, O. Chapet, M. T. Closon-Dejardin, et al. 2006. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J. Clin. Oncol. 24:4620-4625.
41. De Roock, W., B. Claes, D. Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas, et al. 2010. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11:753-762.
42. Liao, X., P. Lochhead, R. Nishihara, T. Morikawa, A. Kuchiba, M. Yamauchi, et al. 2012. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 367:1596-1606.
43. Domingo, E., D. N. Church, O. Sieber, R. Ramamoorthy, Y. Yanagisawa, E. Johnstone, et al. 2013. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J. Clin. Oncol. 31:4297-4305.
44. Kothari, N, R. D. Kim, P. Gibbs, T. J. Yeatman, M. J. Schell, J. Desai, et al. 2014. Regular aspirin (ASA) use and survival in patients with PIK3CA-mutated metastatic colorectal cancer (CRC). J. Clin. Oncol. 32(Suppl. 3).
45. Hutchins, G., K. Southward, K. Handley, L. Magill, C. Beaumont, J. Stahlschmidt, et al. 2011. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 29:1261-1270.
46. Kalinsky, K., L. M. Jacks, A. Heguy, S. Patil, M. Drobnjak, U. K. Bhanot, et al. 2009. PIK3CA mutation associates with improved outcome in breast cancer. Clin. Cancer Res. 15:5049-5059.
47. Dong, Y., X. Yang, O. Wong, X. Zhang, Y. Liang, Y. Zhang, et al. 2012. PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3′-kinase pathway alterations might be associated with favorable prognosis. Hum. Pathol. 43:1197-1205.
48. Rahman, M., K. Nakayama, M. T. Rahman, N. Nakayama, M. Ishikawa, A. Katagiri, et al. 2012. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum. Pathol. 43:2197-2206.
49. Shigaki, H., Y. Baba, M. Watanabe, A. Murata, T. Ishimoto, M. Iwatsuki, et al. 2013. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin. Cancer Res. 19:2451-2459.
50. Baba, Y., K. Nosho, K. Shima, M. Hayashi, J. A. Meyerhardt, A. T. Chan, et al. 2011. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer 117:1399-1408.